NCT07111546View on ClinicalTrials.gov

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

December 26, 2026

Study Completion Date

December 26, 2026

Conditions
Advanced Solid Tumour
Interventions
DRUG

LBL-024 for Injection

Intravenous infusion.

DRUG

Durvalumab Injection

Intravenous infusion.

DRUG

Cisplatin Injection

Intravenous infusion.

DRUG

Gemcitabine Hydrochloride for Injection

Intravenous infusion.

DRUG

Bevacizumab Injection

Intravenous infusion.

Trial Locations (5)

200032

Zhongshan Hospital of Fudan University, Shanghai

310016

Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

330029

Jiangxi Cancer Hospital, Nanchang

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY